Regencell Bioscience Holdings Securities Class Action
Regencell Bioscience Holdings · Regencell securities · New Filing
About this case
A securities class action was filed in the U.S. District Court for the District of Maryland on behalf of investors who purchased or acquired Regencell securities from October 28, 2024, through October 31, 2025. The complaint alleges that Regencell and certain officers made materially false or misleading statements concerning the company’s vulnerability to market manipulation, share-price volatility, and related regulatory and legal risks; the matter was filed under docket number 26-cv-01602.
Case overview
- Defendant company
- Regencell Bioscience Holdings
- Product or service
- Regencell securities
- Court case number
- 26-cv-01602
- Case status
- New Filing
- Lawsuit type
- Securities
- Reported harm
- Other
Important dates
- Lead Plaintiff Application
Participation information
Availability is based on each listed participation option and its deadline.
Lead Plaintiff Application
Investors who purchased or otherwise acquired Regencell securities during the class period from October 28, 2024, through October 31, 2025, could seek appointment as lead plaintiff.
A motion seeking appointment as lead plaintiff was required to be filed with the court by June 23, 2026.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.
- Regencell Securities Class Action
Barchart.com ·
- Regencell Bioscience Holdings Securities Class Action
Eagle-Tribune ·